Dimethyl sulfoxide: a central player since the dawn of cryobiology, is efficacy balanced by toxicity?
Maooz AwanIryna BuriakRoland FleckBarry FullerAnatoliy GoltsevJulie KerbyMark LowdellPavel MerickaAlexander PetrenkoYuri PetrenkoOlena RogulskaAlexandra StolzingOlena Y RogulskaPublished in: Regenerative medicine (2020)
Dimethyl sulfoxide (DMSO) is the cryoprotectant of choice for most animal cell systems since the early history of cryopreservation. It has been used for decades in many thousands of cell transplants. These treatments would not have taken place without suitable sources of DMSO that enabled stable and safe storage of bone marrow and blood cells until needed for transfusion. Nevertheless, its effects on cell biology and apparent toxicity in patients have been an ongoing topic of debate, driving the search for less cytotoxic cryoprotectants. This review seeks to place the toxicity of DMSO in context of its effectiveness. It will also consider means of reducing its toxic effects, the alternatives to its use and their readiness for active use in clinical settings.
Keyphrases
- single cell
- bone marrow
- cell therapy
- oxidative stress
- end stage renal disease
- randomized controlled trial
- induced apoptosis
- ejection fraction
- systematic review
- mesenchymal stem cells
- magnetic resonance imaging
- chronic kidney disease
- cell death
- prognostic factors
- computed tomography
- drinking water
- cell cycle arrest
- peritoneal dialysis
- magnetic resonance
- stem cells
- endoplasmic reticulum stress
- signaling pathway
- sickle cell disease